Cited 0 time in
A Novel Mutation in the GATA1 Gene Associated with Acute Megakaryoblastic Leukemia in a Korean Down Syndrome Patient
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kim, In-Suk | - |
| dc.contributor.author | Park, Eun Sil | - |
| dc.contributor.author | Lim, Jae Young | - |
| dc.contributor.author | Ki, Chang-Seok | - |
| dc.contributor.author | Chi, Hyun Sock | - |
| dc.date.accessioned | 2022-12-27T05:55:36Z | - |
| dc.date.available | 2022-12-27T05:55:36Z | - |
| dc.date.issued | 2008-12 | - |
| dc.identifier.issn | 1011-8934 | - |
| dc.identifier.issn | 1598-6357 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/27189 | - |
| dc.description.abstract | Although acquired mutations in the GATA1 gene have been reported for Down syndrome-related acute megakaryoblastic leukemia (DS-AMKL) in Caucasians, this is the first report of a Korean Down syndrome patient with AMKL carrying a novel mutation of the GATA1 gene. A 3-yr-old Korean girl with Down syndrome was admitted to our hospital complaining of pallor and fever. The findings of a peripheral blood smear and bone marrow study were compatible with the presence of AMKL. A chromosome study showed 48,XX,-7,+21c,+21,+r[3]/47,XX,+21c[17]. Following GATA1 gene mutation analysis, a novel mutation, c. 145dupG (p.Ala49Glyf-sX18), was identified in the N-terminal activation domain of the GATA1 gene. This mutation caused a premature termination at codon 67 and expression of an abnormal GATA-1 protein with a detective N-terminal activation domain, and the absence of full-length GATA-1 protein. This case demonstrates that a leukemogenic mechanism for DS-AMKL is contributed by a unique collaboration between overexpressed genes from trisomy 21 and an acquired GATA1 mutation previously seen in Caucasians and now in a Korean patient. | - |
| dc.format.extent | 4 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
| dc.title | A Novel Mutation in the GATA1 Gene Associated with Acute Megakaryoblastic Leukemia in a Korean Down Syndrome Patient | - |
| dc.type | Article | - |
| dc.publisher.location | 대한민국 | - |
| dc.identifier.doi | 10.3346/jkms.2008.23.6.1105 | - |
| dc.identifier.scopusid | 2-s2.0-60549103798 | - |
| dc.identifier.wosid | 000262192100029 | - |
| dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.23, no.6, pp 1105 - 1108 | - |
| dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
| dc.citation.volume | 23 | - |
| dc.citation.number | 6 | - |
| dc.citation.startPage | 1105 | - |
| dc.citation.endPage | 1108 | - |
| dc.type.docType | Article | - |
| dc.identifier.kciid | ART001299866 | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.description.journalRegisteredClass | kci | - |
| dc.relation.journalResearchArea | General & Internal Medicine | - |
| dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
| dc.subject.keywordPlus | TRANSIENT LEUKEMIA | - |
| dc.subject.keywordPlus | MYELOPROLIFERATIVE DISORDER | - |
| dc.subject.keywordPlus | POINT MUTATIONS | - |
| dc.subject.keywordPlus | MALIGNANCIES | - |
| dc.subject.keywordPlus | RUNX1 | - |
| dc.subject.keywordAuthor | Leukemia | - |
| dc.subject.keywordAuthor | Megakaryoblastic | - |
| dc.subject.keywordAuthor | Acute | - |
| dc.subject.keywordAuthor | Down Syndrome | - |
| dc.subject.keywordAuthor | GATA1 Transcription Factor | - |
| dc.subject.keywordAuthor | Korea | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
